LENSAR designs, develops, and markets femtosecond laser systems for cataract surgery and corneal astigmatism correction. The company's primary offering, the LENSAR Laser System, integrates imaging, procedure planning, and precision laser delivery to assist surgeons in achieving specific visual outcomes. The system addresses both age-related cataracts and surgically induced or pre-existing astigmatism in patients undergoing cataract procedures.
The company also offers the ALLY Robotic Cataract Laser System, a compact platform designed to enable sterile, laser-assisted cataract surgery within standard operating rooms. This system represents an alternative form factor to traditional laser cataract platforms. LENSAR operates primarily in the United States market, where it markets these devices to ophthalmic surgical centers and hospitals.
The company employs approximately 140 people and is headquartered in Orlando, Florida. As a commercial-stage medical device manufacturer, LENSAR generates revenue through device sales and related service offerings to the ophthalmic surgery market. The company was incorporated in Delaware in 2004 and is listed on Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-2.73 | $-2.73 | -108.4% | |
| 2023 | $-1.31 | $-1.31 | +33.2% | |
| 2022 | $-1.96 | $-1.96 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — |